Assistant Professor, Medicine, University of Miami School of Medicine
Hematology
Dr. Ronan T. Swords, MD
|
|
Give Review
Ronan T. Swords, MD practices Hematology. He has 1 awards "CMS Meaningful Use Stage 1 Certification". Ronan Swords is a published doctor as well. He has 52 publications published. The latest was: Routine interim disease assessment in patients undergoing induction chemotherapy for acute myeloid leukemia: Can we do better? He accepts Medicare.
Publications
- Routine interim disease assessment in patients undergoing induction chemotherapy for Acute myeloid leukemia: Can we do better?
- Targeted therapy of Acute myeloid leukemia.
- Pevonedistat (MLN4924), a First-in-Class NEDD8-activating enzyme inhibitor, in patients with Acute myeloid leukaemia and myelodysplastic syndromes: a phase 1 study.
- Novel myelofibrosis treatment strategies: potential partners for combination therapies.
- New prospects for drug development: the hedgehog pathway revealed. Focus on hematologic malignancies.
- Personalized medicine for Acute myelogenous leukemia-At the entrance gate.
- A prospective randomised study of a rotary powered device (OnControl) for bone marrow aspiration and biopsy.
- Inhibition of NEDD8-activating enzyme: a novel approach for the treatment of Acute myeloid leukemia.
- Progression of myelodysplasia during low-dose methotrexate therapy in rheumatoid arthritis.
- Sacral insufficiency fracture complicated by epidural haematoma and cauda equina Syndrome in a patient with multiple myeloma.
- Imatinib in relapsed or refractory Philadelphia chromosome-positive Acute lymphoblastic leukaemia: a viewpoint by Ronan Swords.
- Bone biopsy of new suspicious bone lesions in patients with primary carcinoma: prevalence and probability of an alternative diagnosis.
- Vorinostat enhances the activity of temsirolimus in renal Cell carcinoma through suppression of survivin levels.
- Spurious elevation of the cerebrospinous fluid white Cell counts in three patients receiving liposomal cytarabine as part of post-remission therapy.
- Powered bone marrow biopsy procedures produce larger core specimens, with less pain, in less time than with standard manual devices.
- Autologous stem Cell transplantation in myeloma: the St James''s Hospital experience, 1997-2003.
- Successful induction of molecular remission with single-agent anti-CD33 antibody (gemtuzumab ozogamicin) in chemotherapy-refractory relapse of Acute myeloid leukaemia ...
- Anagrelide-induced visual hallucinations in a patient with essential thrombocythemia.
- Myelodysplastic patients with raised percentage of hypochromic red Cells have evidence of functional iron deficiency.
- Treatment of refractory fludarabine induced autoImmune haemolytic with the anti-CD20 monoclonal antibody rituximab.
- Acute lymphoblastic leukemia presenting with avascular necrosis of the elbow.
- Nelarabine activity in Acute biphenotypic leukemia.
- Troxacitabine in Acute leukemia.
- Recent advances in the diagnosis and therapy of Richter's Syndrome.
- Troxacitabine in Leukemia.
- CML clonal evolution with resistance to single agent imatinib therapy.
- Class effects of tyrosine kinase inhibitors in the treatment of chronic myeloid Leukemia.
- Nilotinib: optimal therapy for patients with chronic myeloid Leukemia and resistance or intolerance to imatinib.
- Targeting sarcomas: novel biological agents and future perspectives.
- The pim kinases: new targets for drug development.
- Clinical utility of PET/CT in Lymphoma.
- Treatment of Acute lymphoblastic leukaemia : a new era.
- Interstitial pneumonitis following rituximab therapy for Immune thrombocytopenic purpura (ITP).
- Autophagy inhibition enhances vorinostat-induced apoptosis via ubiquitinated protein accumulation.
- Emerging therapeutic options for Philadelphia-positive Acute lymphocytic leukemia.
- Clinical activity of laromustine (Onrigin™) in hematologic malignancies.
- Clofarabine in the treatment of poor risk Acute myeloid leukaemia.
- Novel Abl kinase inhibitors in chronic myeloid leukemia in blastic phase and Philadelphia chromosome-positive Acute lymphoblastic leukemia.
- Cdc7 kinase - a new target for drug development.
- Amonafide: a future in treatment of resistant and secondary Acute myeloid leukemia?
- Elacytarabine, a novel 5'-elaidic acid derivative of cytarabine, and idarubicin combination is active in refractory Acute myeloid leukemia.
- Serosal inflammation (pleural and pericardial effusions) related to tyrosine kinase inhibitors.
- Second-generation tyrosine kinase inhibitors as therapy for chronic myeloid Leukemia.
- Targeting HSP90 for cancer therapy.
- Heat shock protein 90 regulates the expression of Wilms tumor 1 protein in myeloid Leukemias.
- Optimizing outcomes in patients with chronic myeloid Leukemia in chronic phase: comparative safety profiles of newer agents.
- Emerging drugs in the treatment of pancreatic cancer.
- Rotary powered device for bone marrow aspiration and biopsy yields exCellent specimens quickly and efficiently.
- The PIM kinases in hematological cancers.
- Current status of agents active against the T315I chronic myeloid Leukemia phenotype.
- Targeting protein neddylation: a novel therapeutic strategy for the treatment of cancer.
Procedures Preformed
- HPC Transplantation (Stem Cell Transplant)
Conditions Treated
- Acute Leukemia
- Anemia
- Antiphospholipid Syndrome (APS)
- Burkitt's Lymphoma
- View All
Doctors Specialties
- Hematology
Accepted Insurances
Awards
- CMS Meaningful Use Stage 1 Certification
Drug Facts
| NPI NUMBER | 1720216401 | |
| NPPES Provider LastName | SWORDS | |
| NPPES Provider FirstName | RONAN | |
| NPPES Provider ZIPCode | 331361002 | |
| NPPES Provider State | FL | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 122.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1720216401 |
| Last Name Of The Provider | SWORDS |
| First Name Of The Provider | RONAN |
| View All |
Similar Doctors
|
|
Dr. Elizabeth T. Velasquez, MD |
|
Dr. Sara M. Garrido, MD
 This Doctor is OpenDoctor Recommended.
|
|
Dr. Lisa D. Reale, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Niramol Savaraj, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. William J. Harrington Jr., MD |
|
|
Dr. Bojana B. Bjekic-Bhardwaj, MD |
|
|
Dr. Ruth J. Ratzan, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jaime R. Merchan, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jennifer R. Chapman-Fredricks, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Vinicius Ernani, MD |
|
|
Dr. Esmildo E. Machado, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ana C. Sandoval Leon, MD |
|
|
Dr. Sean M. Warsch, MD |